Nanoparticle-Based Drug Delivery Systems for Arsenic Trioxide in Cancer Therapy
Summary
Arsenic trioxide (ATO) has proven efficacy against acute promyelocytic leukaemia but faces considerable challenges in the treatment of solid tumours due to rapid systemic clearance, off-target toxicity and poor accumulation within the tumour microenvironment. Nanoparticle-based delivery systems address these limitations by encapsulating ATO within biocompatible carriers that prolong circulation time, enhance tumour uptake and enable controlled release. A variety of platforms—liposomes, polymeric nanoparticles, inorganic nanocrystals and biomimetic membranes—have been engineered to improve ATO solubility, shield healthy tissues and exploit the enhanced permeability and retention effect in malignant tissues. Surface modifications with targeting ligands or cell-membrane coatings further refine specificity, while pH-responsive or enzyme-triggered release mechanisms ensure on-site liberation of the active arsenite species. Beyond monotherapy, co-delivery of ATO with synergistic agents such as doxorubicin or gene silencers has demonstrated potent combinatorial effects, overcoming drug resistance in refractory cancers. Image-guided approaches integrate contrast agents into the nanoparticle core, permitting real-time monitoring of biodistribution and release kinetics. Together, these advances are paving the way towards safer, more effective applications of ATO in a broad spectrum of solid malignancies.
Research from Nature Portfolio
Recent studies have demonstrated a convertible imaging–therapeutic nanoplatform in which manganese ions co-precipitated with arsenite inside liposomes to generate a T2-weighted magnetic resonance imaging (MRI) shadow. Upon endosomal acidification in glioblastoma cells, the complex disassembles to release arsenite and Mn2+, converting the MRI signal to a bright T1 contrast and confirming intracellular ATO delivery. Another foundational report described a dual-drug silica–iron oxide nanocomposite loaded with both ATO and doxorubicin, exhibiting pH-triggered release and synergistic induction of apoptosis in multidrug-resistant hepatocellular carcinoma cells. In this system, arsenite inhibited poly(ADP-ribose) polymerase-1 (PARP-1), enhancing DNA damage by doxorubicin and overcoming chemoresistance through simultaneous delivery and on-demand release.
Nanoparticle-Based Drug Delivery Systems for Arsenic Trioxide in Cancer Therapy publication trend
The graph below shows the total number of articles in nanoparticle-based drug delivery systems for arsenic trioxide in cancer therapy across all publications each year (not limited to Nature Index journals).
Technical terms
Liposome: A vesicular nanocarrier composed of phospholipid bilayers, used to encapsulate hydrophilic or lipophilic drugs for enhanced delivery.
Nanocarrier: A nanoscale vehicle—such as a polymeric nanoparticle, liposome or inorganic particle—designed to transport therapeutic or diagnostic agents.
pH-responsive release: A drug-release mechanism in which acidic tumour or endosomal environments trigger nanoparticle disassembly and cargo liberation.
Theranostics: Integrated systems combining therapeutic delivery and diagnostic imaging within a single nanoparticle platform.
Encapsulation efficiency: The proportion of drug successfully loaded into a nanocarrier relative to the initial amount used in formulation.
Multidrug resistance: A cellular phenotype in which cancer cells evade conventional chemotherapy, often through efflux pumps or enhanced DNA repair.
References
- Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers. Journal of Biomedical Research (2017).
- Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Medicinal Research Reviews (2021).
- Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs. Scientific Reports (2015).
- Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. Scientific Reports (2016).
- Mineral medicine: from traditional drugs to multifunctional delivery systems. Chinese Medicine (2022).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.